Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : Alpmf save search
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.82%
H: 0.0%
C: -2.54%
keytruda license bladder cancer treatment medical application advanced
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.65%
H: 3.36%
C: 3.17%
japan approved cancer treatment
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -0.54%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 2.26%
H: 0.0%
C: -2.65%
chmp positive cancer treatment
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-02-15 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -2.99%
H: 3.82%
C: 3.54%
keytruda granted review bladder cancer treatment advanced
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-31 (Crawled : 02:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.56%
H: 1.25%
C: -0.33%
keytruda drug japan bladder cancer treatment application advanced
European Medicines Agency Validates Type II Variation Application for PADCEV™ (enfortumab vedotin) with KEYTRUDA®(pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-01-26 (Crawled : 17:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -6.38%
H: 0.88%
C: 0.88%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.09%
H: 0.17%
C: -0.3%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.58%
H: 1.01%
C: -0.58%
keytruda bladder cancer treatment application advanced
Castration-Resistant Prostate Cancer (CRPC) Treatment Market size to grow by USD 5.98 billion from 2023 to 2028, North America to account for 47% of market growth- Technavio
Published: 2024-01-09 (Crawled : 03:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: -3.88%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.22%
H: 0.0%
C: -0.72%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.46%
H: 0.74%
C: -0.19%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.92%
H: 0.63%
C: -0.25%
america cancer treatment market
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Published: 2023-12-17 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.7%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.79%
H: 0.35%
C: -0.26%
UVV | $51.46 1.9% 0.0% 190K
|
Consumer Non-Durables
|
| O: 0.0%
H: 0.05%
C: -1.86%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.09%
H: 1.41%
C: 0.52%
children treatment ema
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
Published: 2023-12-10 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -1.04%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -2.49%
H: 5.4%
C: 1.89%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.73%
H: 0.78%
C: 0.73%
approved treatment
FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 3.87%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -3.37%
H: 4.51%
C: 4.51%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -4.92%
H: 1.48%
C: -0.21%
padcev fda license review bladder cancer treatment application grants
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting
Published: 2023-11-17 (Crawled : 04:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.38%
H: 1.79%
C: 1.79%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.5%
H: 0.3%
C: 0.0%
xtandi fda approved cancer treatment
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Players - MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics
Published: 2023-10-30 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.67%
H: 3.16%
C: 2.75%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
positive treatment growth market
Global Acute Myeloid Leukemia (AML) Treatment Market Trends Analysis Report 2023-2028 - Personalized Medicine and Patient Advocacy Drive Opportunities
Published: 2023-10-20 (Crawled : 10:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -4.45%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -3.95%
H: 0.0%
C: -0.72%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -2.89%
H: 3.67%
C: 2.85%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.42%
H: 0.54%
C: 0.11%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.16%
C: -0.64%
report treatment global trends leukemia market
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
Published: 2023-10-19 (Crawled : 06:00) - globenewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.71%
H: 0.0%
C: -2.2%
treatment acquisition antifungal infections
Global Vulvovaginal Candidiasis Treatment Market Research Report 2023-2028 - Demand for Cost-effective Vulvovaginal Candidiasis Treatment Soars with Growing Geriatric Population
Published: 2023-10-04 (Crawled : 23:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.59%
H: 0.29%
C: 0.22%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.42%
H: 0.99%
C: 0.06%
SCYX | $1.44 2.49% 2.43% 130K
|
Health Technology
|
| O: 0.45%
H: 4.04%
C: 0.45%
CDTX | $0.6855 -5.06% -5.32% 350K
|
Health Technology
|
| O: 0.39%
H: 10.33%
C: 3.9%
report treatment candidiasis research global growing market
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Published: 2023-09-12 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.03%
H: 1.04%
C: -0.37%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.18%
H: 1.2%
C: -0.38%
xtandi cancer treatment
Global Autoimmune Treatment Market Soars to $288.32 Billion by 2028, Driven by a 7.72% CAGR from 2023
Published: 2023-08-25 (Crawled : 02:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -3.27%
H: 3.65%
C: 3.36%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -4.14%
H: 5.37%
C: 4.39%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.67%
H: 0.37%
C: 0.26%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.51%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.11%
H: 0.44%
C: -0.22%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.73%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.22%
H: 0.6%
C: 0.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.19%
H: 0.25%
C: -0.28%
treatment global market
Onychomycosis Treatment Market size to grow by USD 1,776.53 million from 2022 to 2027; Growth driven by increasing prevalence of onychomycosis - Technavio
Published: 2023-08-15 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.02%
H: 0.0%
C: -1.05%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.78%
H: 0.39%
C: -2.39%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.44%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.51%
H: 0.24%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
treatment growth market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.